Production (Stage)
NRx Pharmaceuticals, Inc.
NRXP
$3.27
$0.3311.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 39.28% | -459.33% | 79.45% | -20.97% | -50.69% |
| Total Depreciation and Amortization | -- | -50.00% | 100.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -60.94% | -- | -- | -- | -- |
| Total Other Non-Cash Items | -87.29% | 1,917.86% | -131.83% | 301.93% | 144.35% |
| Change in Net Operating Assets | 100.00% | -300.00% | -98.59% | 33.23% | -5.57% |
| Cash from Operations | -65.87% | 9.02% | 9.99% | 30.21% | -15.01% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 20.83% | 40.70% | -- | -- | -- |
| Total Debt Repaid | 91.52% | -42.78% | -264,300.00% | 99.95% | -69.29% |
| Issuance of Common Stock | -- | -100.00% | -93.03% | 23.22% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -122.85% | -0.39% | -- | -- | -- |
| Cash from Financing | 300.26% | -7.74% | -34.61% | 695.19% | 135.39% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,122.17% | 19.44% | -143.52% | 117.67% | 23.94% |